@article{Shkala_Kleban_Cherpak_Shkala_Karapetian_Volkovska_2021, title={Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus}, url={https://iej.zaslavsky.com.ua/index.php/journal/article/view/665}, DOI={10.22141/2224-0721.5.69.2015.75180}, abstractNote={<p>The article presents the results of using new antihyperglycemic drug — a selective inhibitor of the sodium-glucose cotransporter type 2 — dapagliflozin in patients with type 2 diabetes mellitus. The influence of this drug on the effectiveness of glycemic control, blood pressure level, lipid profile, body weight has been analyzed, compliance has been assessed. According to the practice of dapagliflozin application in the combination antidiabetic therapy, the drug is easy to use, provides sufficient glycemic control (significant decrease in glycated hemoglobin by an average of 0.98 %), reduces body weight in the presence of obesity or overweight (a decrease in the body mass index by an average of 1.78 kg/m2), has a positive effect on blood pressure, has no significant effect on the correction of dyslipidemia in the presence of transient adverse reactions in some women in the form of cystitis and vulvovaginitis, does not require discontinuation of treatment. Application of dapagliflozin in combination hypoglycemic therapy in patients with diabetes type 2 is suitable for achieving compensation.</p>}, number={5.69}, journal={INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)}, author={Shkala, L.V. and Kleban, Ya.I. and Cherpak, O.V. and Shkala, O.V. and Karapetian, O.A. and Volkovska, T.H.}, year={2021}, month={Dec.}, pages={100–104} }